Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

BACKGROUND: In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab demonstrated a high objective response rate, including complete responses in patients with advanced melanoma. METHODS: In this double-blind study, 142 treatment-naïve patient...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Postow, Michael A., Chesney, Jason, Pavlick, Anna C., Robert, Caroline, Grossmann, Kenneth, McDermott, David, Linette, Gerald P., Meyer, Nicolas, Giguere, Jeffrey K., Agarwala, Sanjiv S., Shaheen, Montaser, Ernstoff, Marc S., Minor, David, Salama, April K., Taylor, Matthew, Ott, Patrick A., Rollin, Linda M., Horak, Christine, Gagnier, Paul, Wolchok, Jedd D., Hodi, F. Stephen
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5744258/
https://ncbi.nlm.nih.gov/pubmed/25891304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1414428
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados